Clinical trials: Plasmodium Vivax Malaria
Plasmodium Vivax Malaria, Malaria
FocaL Mass Drug Administration for Vivax Malaria Elimination
FLAME is an open-label cluster-randomized controlled trial that aims to determine the effectiveness of focal mass drug administration (fMDA) to reduce the incidence of Plasmodium vivax malaria in the Loreto Department in Peru.
- Trial name
- FLAME (NCT05690841)
- Testing
- Focal Mass Drug Administration (fMDA)
- Where
- Peru
- Volunteers
- 7,530 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria
Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic
This study assesses the effectiveness and feasibility of enhanced reactive case detection (RACD) targeting high-risk villages and forest workers for reducing Plasmodium falciparum and Plasmodium vivax transmission in southern Lao…
- Trial name
- COMBAT (NCT04416945)
- Testing
- Household Reactive Case Detection, RACD of cases' co-workers/co-travelers, Case Management and Follow-up
- Where
- Laos
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria
Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand
This study assesses the effectiveness of reactive focal mass drug administration (rfMDA), targeting both village and forest working populations, compared to control for reducing the health promotion hospital-level (sub-district)…
- Trial name
- COMBAT (NCT05052502)
- Testing
- Case Management and Follow-up, Reactive focal mass drug administration (rfMDA)
- Where
- Thailand
- Volunteers
- 14,977 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria, Mass Drug Administration
Efficacy of Focal Primaquine Mass Administration for Eliminating Plasmodium Vivax Malaria in Northern Myanmar
Plasmodium vivax has become the predominant species in the Greater Mekong Subregion and is a major challenge for regional malaria elimination.
- Conditions
- Malaria, Mass Drug Administration, Myanmar, Plasmodium Vivax
- Trial name
- NCT06392152
- Testing
- Focal Mass Drug Administration with Primaquine
- Where
- Burma
- Volunteers
- 1,208 people, healthy volunteers welcome
- Sponsor
- Pyae Linn Aung
Plasmodium Vivax Malaria
Papua New Guinean Duffy Negativity And Vivax Malar
The purpose of this study is to learn more about vivax malaria in very young children, how the growth of children is affected by malaria infections, and how inherited traits protect children from getting malaria.
- Trial name
- NCT00138489
- Where
- Papua New Guinea
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium Vivax Infection, Plasmodium Vivax Clinical Episode
Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity
This study specifically seeks to quantify the contribution of relapes to the burden of P. vivax infections and disease by determining on the effect of radical pre-erythrocytic and erythrocytic clearance on subsequent rates of…
- Conditions
- Plasmodium Vivax Infection, Plasmodium Vivax Clinical Episode, Plasmodium Falciparum Infection, Plasmodium Falciparum Clinical Episode
- Trial name
- NCT02143934
- Testing
- Primaquine, Chloroquine, Artemether Lumefantrine
- Where
- Papua New Guinea
- Volunteers
- 524 people, healthy volunteers welcome
- Sponsor
- Papua New Guinea Institute of Medical Research